Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study

被引：0
|
作者：
Philip J. Mease
Dafna D. Gladman
Denis Poddubnyy
Soumya D. Chakravarty
May Shawi
Alexa P. Kollmeier
Xie L. Xu
Stephen Xu
Atul Deodhar
Xenofon Baraliakos
机构：
[1] Swedish Medical Center/Providence St. Joseph Health and University of Washington,Department of Rheumatology
[2] Rheumatology Research,Centre for Prognosis Studies in the Rheumatic Diseases
[3] Toronto Western Hospital,Rheumazentrum Ruhrgebiet
[4] Charité-Universitatsmedizin Berlin,undefined
[5] Janssen Scientific Affairs,undefined
[6] LLC,undefined
[7] Drexel University College of Medicine,undefined
[8] Janssen Research & Development,undefined
[9] LLC,undefined
[10] Janssen Research & Development,undefined
[11] LLC,undefined
[12] Janssen Research & Development,undefined
[13] LLC,undefined
[14] Oregon Health & Science University,undefined
[15] Ruhr-University Bochum,undefined
来源：
Rheumatology and Therapy | 2023年 / 10卷
关键词：
Psoriatic arthritis; Axial; Biologics; Guselkumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1637 / 1653
页数：16
相关论文
共 50 条
  • [1] Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
    Mease, Philip J.
    Gladman, Dafna D.
    Poddubnyy, Denis
    Chakravarty, Soumya D.
    Shawi, May
    Kollmeier, Alexa P.
    Xu, Xie L.
    Xu, Stephen
    Deodhar, Atul
    Baraliakos, Xenofon
    [J]. RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1637 - 1653
  • [2] EFFICACY OF GUSELKUMAB ACROSS BASDAI COMPONENTS IN TREATING AXIAL-RELATED SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
    Behrens, F.
    Mease, P. J.
    Helliwell, P.
    Shawi, M.
    Noel, W.
    Chakravarty, D.
    Kollmeier, A.
    Xu, X. L.
    Xu, S.
    Wang, Y.
    Baraliakos, X.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1289 - 1290
  • [3] Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies
    Behrens, Frank
    Mease, Philip
    Helliwell, Philip S.
    Shawi, May
    Noel, Wim
    Chakravarty, Soumya
    Xu, Alexa Kollmeier Xie
    Xu, Xie
    Xu, Stephen
    Wang, Yanli
    Baraliakos, Xenofon
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3778 - 3780
  • [4] EFFICACY OF GUSELKUMAB ACROSS BASDAI COMPONENTS IN TREATING AXIAL-RELATED SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE-3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
    Behrens, F.
    Mease, P. J.
    Helliwell, P. S.
    Shawi, M.
    Noel, W.
    Chakravarty, S. D.
    Kollmeier, A. P.
    Xu, X. L.
    Xu, S.
    Wang, Y.
    Baraliakos, X.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : 1244 - 1245
  • [5] The Effect of Guselkumab on Work Productivity in Biologic-Naive Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Curtis, Jeffrey R.
    McInnes, Iain B.
    Rahman, Proton
    Gladman, Dafna D.
    Peterson, Steven
    Agarwal, Prasheen
    Yang, Feifei
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Shiff, Natalie J.
    Zhou, Bei
    Han, Chenglong
    Shawi, May
    Tillett, William
    Mease, Philip J.
    [J]. ADVANCES IN THERAPY, 2022, 39 (10) : 4613 - 4631
  • [6] The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Jeffrey R. Curtis
    Iain B. McInnes
    Proton Rahman
    Dafna D. Gladman
    Steven Peterson
    Prasheen Agarwal
    Feifei Yang
    Alexa P. Kollmeier
    Elizabeth C. Hsia
    Natalie J. Shiff
    Bei Zhou
    Chenglong Han
    May Shawi
    William Tillett
    Philip J. Mease
    [J]. Advances in Therapy, 2022, 39 : 4613 - 4631
  • [7] The Effect of Guselkumab on General Health State in Biologic-Naive Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Curtis, Jeffrey R.
    McInnes, Iain B.
    Rahman, Proton
    Gladman, Dafna D.
    Yang, Feifei
    Peterson, Steven
    Agarwal, Prasheen
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Han, Chenglong
    Shiff, Natalie J.
    Shawi, May
    Tillett, William
    Mease, Philip J.
    [J]. ADVANCES IN THERAPY, 2022, 39 (10) : 4632 - 4644
  • [8] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice B.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    van der Heijde, Desiree
    McInnes, Iain B.
    [J]. LANCET, 2020, 395 (10230): : 1126 - 1136
  • [9] Efficacy of guselkumab (GUS) on axial-related endpoints in patients with active psoriatic arthritis (PsA) with imaging-confirmed sacroiliitis: Results through week 52 from DISCOVER-1 and DISCOVER-2
    Gottlieb, Alice B.
    Merola, Joseph F.
    Armstrong, April W.
    Savage, Laura
    Chakravarty, Soumya D.
    Kollmeier, Alexa P.
    Zhou, Bei
    Yang, Ya-Wen
    Sweet, Kristen
    Boehncke, Wolf-Henning
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB39 - AB39
  • [10] The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Jeffrey R. Curtis
    Iain B. McInnes
    Proton Rahman
    Dafna D. Gladman
    Feifei Yang
    Steven Peterson
    Prasheen Agarwal
    Alexa P. Kollmeier
    Elizabeth C. Hsia
    Chenglong Han
    Natalie J. Shiff
    May Shawi
    William Tillett
    Philip J. Mease
    [J]. Advances in Therapy, 2022, 39 : 4632 - 4644
12345